Hello, my name is Dr. Dieter Wolf.
I'm a professor in the Tumor Initiation and Maintenance
Program at Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California.
I also hold an appointment in the school of
Pharmaceutical Sciences of Xiamen University in China.
This lecture is going to be about
"Mitochondrial Inhibition as a Novel Therapeutic Approach in Drug-Resistant Cancer".
Drug resistance is one of the major problems in cancer therapy.
While scientists and physicians avail of plenty
of drugs that kill cancer cells often in a selective manner,
typically tumors develop resistance to these drugs relatively quickly.
In our studies, we have addressed prostate cancer as a paradigm of drug resistance.
Prostate cancer is the most common male malignancy
and the second most common cause of death from cancer in men.
There are approximately 250,000 new cases diagnosed each year.
And there are over two million patients living in the US with numbers increasing steadily.
Due to the large number of patients,
the prostate cancer drug market is huge and has
doubled from 8 to 16 billion US dollars in the past five years.
The main problem with prostate cancer comes when the standard of care drugs stop working.
This is when the disease progresses to drug resistance,
or so called castration resistant prostate cancer or CRPC.
So as the naming is saying,